Skin Cancer

A poster presentation from SBS 2023 reviewed the clinician satisfaction of tirbanibulin for the treatment of actinic keratosis.

Laura Ferris, MD, PhD, discusses the future landscape of artificial intelligence and skin cancer detection at SBS 2023.

David Goldberg, MD, JD, explores the increasing rates of melanoma in the US and how to manage melanoma subtypes at SBS 2023.

Merkel cell carcinoma is a rare but highly aggressive type of nonmelanoma skin cancer and Merkel cell polyomavirus is thought to play a major role in its etiology.

The safety of gel manicures is under renewed scrutiny after a new study suggests they can cause DNA damage.

This review will explore various leukemia-related cutaneous findings and discuss the diagnosis and management of these conditions.

In his session at Maui Derm Hawaii 2023, Curtis Cole, PhD, President of Sun & Skin Consulting, LLC, detailed the limitations facing the US Sunscreen industry.

A study published in Future Medicine finds consistent use of the treatment is difficult for patients to maintain in a real-world setting.

A review published in the International Journal of Molecular Sciences described advanced BCC molecular mechanisms and resulting targeted therapies.

Dermatologists have long warned tan seekers about the detrimental effects of ultraviolet exposure and tanning beds, strongly discouraging their use; nasal tanning sprays are no different.

Darrell S. Rigel shares current updates in skin cancer treatments and incidences across the US at Winter Clinical Hawaii.

New clues about the immune system response to MCC may be able to help guide future treatment strategies.

In basal cell carcinoma, the most common type of skin cancer accounting for 80% of all non-melanoma skin cancers, one of the leading options for cases that fall into this category is targeted treatment with Hedgehog pathway inhibitors.

Although Merkel cell carcinoma can develop undetected or at a metastasized site, it usually first appears as a painless lump or nodule on an area of the skin that has been exposed to the sun.

To date, it is unknown what impact potential response-adapted treatment strategies for advanced melanoma may have economically.

New research suggests new pharmacological therapies are associated with a decrease in melanoma-related deaths.

Precision medicine may help improve the diagnosis and management of this aggressive skin cancer.

At the 2022 Fall Clinical Dermatology Conference, a dermatologist shares results of using cemiplimab-rwlc (Libtayo) for basal and squamous cell carcinoma.

At a session at the 2022 Fall Clinical Dermatology Conference, 2 clinicians discuss some of the top testing methods for skin cancer.

At the Melanoma Update of the Annual ASDS Meeting, Tyler Hollmig, MD, looked at complex clinical scenarios when treating melanoma and the continued challenges dermatologists face.

Kimberly Ken, MD, assistant professor of dermatology at Penn State University, discussed crucial methods for advanced melanoma management.

Authors of an oral abstract at the 2022 ASDS Annual Meeting presented their findings on the demographics of who requests total body skin exams to screen for skin cancer.

Precision medicine may help improve the diagnosis and management of melanoma.

Bristol Myers Squibb’s nivolumab shows potential for treatment in earlier stages of melanoma.

At a poster session at the Skin of Color Update meeting in New York City, investigators looked at skin cancer education and prevention among patients with skin of color.

Expert dermatologist, Susan Taylor, MD, FAAD, discusses available sunscreen options to patients.

Susan Taylor, MD, FAAD, discusses FDA regulations for sunscreens.

Susan Taylor, MD, FAAD, addresses gaps in understanding damage to the skin by the general population.

Expert dermatologist Susan Taylor, MD, FAAD, provides education to community dermatologists about the pathophysiology of skin damage

Susan Taylor, MD, FAAD, compares how skin damage can occur in individuals with skin of color compared with individuals with light skin.